Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc.
Your view on HOWL
Overview
What the company does, where it operates, and who runs it.
About Werewolf Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Daniel J. Hicklin
- Headquarters
- 1030 Massachusetts Avenue, Watertown, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Daniel J. Hicklin
- Headquarters
- 1030 Massachusetts Avenue, Watertown, MA, US
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma.
The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Werewolf Therapeutics, Inc., and the rating behind it. HOWL last traded at $0.98; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Werewolf Therapeutics, Inc.. Starting points for Werewolf Therapeutics, Inc.: EPS -$0.71, beta 0.29 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Werewolf Therapeutics, Inc.. Werewolf Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Werewolf Therapeutics, Inc.. Trailing twelve-month EPS for Werewolf Therapeutics, Inc. stands at -$0.71. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Werewolf Therapeutics, Inc.. Werewolf Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Werewolf Therapeutics, Inc. valued side by side against its closest peers. Werewolf Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Werewolf Therapeutics, Inc., and how their positions are changing. At a $47.7M market value, institutional positions materially move Werewolf Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Werewolf Therapeutics, Inc. executives and directors. Shares of Werewolf Therapeutics, Inc. have traded between $0.59 and $2.38 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Werewolf Therapeutics, Inc.. Werewolf Therapeutics, Inc. is a $47.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Werewolf Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Werewolf Therapeutics, Inc.. Coverage tracks Werewolf Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.